- Home
- APLM vs LUXH Comparison
APLM vs LUXH Comparison
Compare APLM & LUXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- LUXH
- Stock Information
- Founded
- APLM 2016
- LUXH 2017
- Country
- APLM United States
- LUXH United States
- Employees
- APLM N/A
- LUXH N/A
- Industry
- APLM Blank Checks
- LUXH Real Estate
- Sector
- APLM Finance
- LUXH Finance
- Exchange
- APLM Nasdaq
- LUXH Nasdaq
- Market Cap
- APLM 15.6M
- LUXH 1.8M
- IPO Year
- APLM N/A
- LUXH N/A
- Fundamental
- Price
- APLM $9.75
- LUXH $0.99
- Analyst Decision
- APLM Strong Buy
- LUXH Hold
- Analyst Count
- APLM 2
- LUXH 2
- Target Price
- APLM $425.00
- LUXH N/A
- AVG Volume (30 Days)
- APLM 107.4K
- LUXH 1.9M
- Earning Date
- APLM 02-15-2025
- LUXH 11-20-2024
- Dividend Yield
- APLM N/A
- LUXH N/A
- EPS Growth
- APLM N/A
- LUXH N/A
- EPS
- APLM N/A
- LUXH N/A
- Revenue
- APLM $2,101,000.00
- LUXH $72,790,178.00
- Revenue This Year
- APLM N/A
- LUXH N/A
- Revenue Next Year
- APLM N/A
- LUXH $15.51
- P/E Ratio
- APLM N/A
- LUXH N/A
- Revenue Growth
- APLM 70.54
- LUXH N/A
- 52 Week Low
- APLM $6.50
- LUXH $0.53
- 52 Week High
- APLM $105.00
- LUXH $481.60
- Technical
- Relative Strength Index (RSI)
- APLM 50.39
- LUXH 38.65
- Support Level
- APLM $7.23
- LUXH $0.53
- Resistance Level
- APLM $8.88
- LUXH $1.19
- Average True Range (ATR)
- APLM 1.37
- LUXH 0.26
- MACD
- APLM 0.21
- LUXH 0.12
- Stochastic Oscillator
- APLM 57.91
- LUXH 27.81
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About LUXH LuxUrban Hotels Inc.
LuxUrban Hotels Inc utilizes a long term lease, asset-light business model to acquire and manage a growing portfolio of short-term rental properties in metropolitan cities. It identifies, acquires, manages, and markets hotel rooms to business and vacation travelers under the consumer brand, LuxUrban. It manages a portfolio of hotel rooms in New York, Washington D.C., Miami Beach, New Orleans and Los Angeles.